We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Polygenic Risk Scores Highlight Potential for Developing Coronary Artery Disease

By LabMedica International staff writers
Posted on 09 Jun 2020
Print article
Image: Micrograph of a coronary artery with the most common form of coronary artery disease (atherosclerosis) and marked luminal narrowing (Photo courtesy of Wikimedia Commons)
Image: Micrograph of a coronary artery with the most common form of coronary artery disease (atherosclerosis) and marked luminal narrowing (Photo courtesy of Wikimedia Commons)
By combining a polygenic risk score with results of more traditional clinical tests, it was possible to identify individuals at high-risk for development of coronary artery disease (CAD) who had not been recognized through standard clinical evaluations alone.

Polygenic risk scores (PRS) for CAD have been shown to identify high-risk individuals more likely to benefit from primary prevention statin therapy. How polygenic CAD risk related to traditional cardiovascular risk factors remained unclear.

Polygenic risk scores reflect a mathematical aggregate of risk conferred by many DNA variants to estimate the likelihood of a specific outcome, such as disease onset in an individual. The scores are the output of statistical models developed using data from large genome-wide association studies (GWAS).

For this study, investigators at Massachusetts General Hospital (Boston, USA) and the Broad Institute of Massachusetts Institute of Technology and Harvard University (Cambridge, USA) applied PRS to 47,108 individuals (11,020 or 23.4% with CAD). who were an average of 60 years old and were receiving care across three health care systems in the United States.

Results revealed that PRS strongly associated with the presence of coronary artery disease. Specifically, individuals with scores in the top 20% were 1.9-times more likely to have developed CAD compared with the remaining 80% of the population. However, those with high PRS were not more likely than others to have been previously recognized as high risk by their primary care physicians.

"We identified a subset of individuals at double the risk of heart attack on the basis of their genes. Despite this elevated risk, these individuals were neither more likely to be flagged as high risk, nor more likely to receive preventive statin therapy per our conventional clinical practices--a consistent finding across all three health systems studied," said first author Dr. Krishna Aragam, a cardiologist at Massachusetts General Hospital. "When coupled with clinical assessments, we estimate that genetic testing may uniquely identify a need for preventive statin therapy in approximately one in every 25 of such patients. Within our present frameworks for heart attack prevention, we speculate that genetic testing may be most immediately useful to guide clinical management for patients otherwise falling in a “gray area” of intermediate risk based on standard clinical factors."

The CAD study was published in the June 9, 2020, online issue of the Journal of the American College of Cardiology.

Related Links:
Massachusetts General Hospital
Broad Institute of Massachusetts Institute of Technology and Harvard University



New
Gold Member
Human Chorionic Gonadotropin Test
hCG Quantitative - R012
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Auto Clinical Chemistry Analyzer
cobas c 703
New
Piezoelectric Micropump
Disc Pump

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.